Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis c virus genotype 1-infected patients

Journal of Virology

Volumn 87, Issue 11, 2013, Pages 6172-6181

  Dietz, Julia ^a   Schelhorn, Sven Eric ^b   Fitting, Daniel ^a   Mihm, Ulrike ^a   Susser, Simone ^a   Welker, Martin Walter ^a   Füller, Caterina ^a   Däumer, Martin ^c   Teuber, Gerlinde ^d   Wedemeyer, Heiner ^e   Berg, Thomas ^f   Lengauer, Thomas ^b   Zeuzem, Stefan ^a   Herrmann, Eva ^g   Sarrazina, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^c Technische University   (Germany)

^d Interdisziplinäres Facharztzentrum Sachsenhausen   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; VIRUS RNA;

ARTICLE; BASE PAIRING; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP SEQUENCING; DRUG EFFICACY; GENETIC PROCEDURES; GENOTYPE; HEPATITIS C; HUMAN; MONOTHERAPY; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION;

ANTIVIRAL AGENTS; BASE SEQUENCE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 84878169408     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02778-12     Document Type: Article

References (56)

1. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. 1972. Broad-spectrum antiviral activity of Virazole: 1-beta-Dribofuranosyl- 1,2,4-triazole-3-carboxamide. Science 177:705-706.
2. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN. 1973. Mechanism of action of 1-D-ribofuranosyl-1,2,4- triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U. S. A. 70:1174 -1178.
3. Crotty S, Cameron C, Andino R. 2002. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J. Mol. Med. 80:86 -95.
4. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH. 1992. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16:649- 654.
5. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L, Dhumeaux D. 2004. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126:703-714.
6. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426 -1432.
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1485-1492.
8. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360:1839 -1850.
9. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705-716.
10. Shimakami T, Lanford RE, Lemon SM. 2009. Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Curr. Opin. Pharmacol. 9:537-544.
11. Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR. 2012. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 55:749 -758.
12. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW. 2007. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46:1548 -1563.
13. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. 2011. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53:32- 41.
14. Rotman Y, Noureddin M, Feld JJ, Guedj J, Witthaus M, Han H, Park YJ, Park SH, Heller T, Ghany MG, Doo E, Koh C, Abdalla A, Gara N, Sarkar S, Thomas E, Ahlenstiel G, Edlich B, Titerence R, Hogdal L, Rehermann B, Dahari H, Perelson AS, Hoofnagle JH, Liang TJ. 8 February 2013. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut [Epub ahead of print.] doi:10.1136/gutjnl -2012-303852.
15. Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S. 2008. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int. 28:1332-1343.
16. Feld JJ, Hoofnagle JH. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967-972.
17. Eigen M. 1993. The origin of genetic information: viruses as models. Gene 135:37- 47.
18. Anderson JP, Daifuku R, Loeb LA. 2004. Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol. 58:183-205.
19. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375-1379.
20. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. 2002. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 76:8505- 8517.
21. Kanda T, Yokosuka O, Imazeki F, Tanaka M, Shino Y, Shimada H, Tomonaga T, Nomura F, Nagao K, Ochiai T, Saisho H. 2004. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J. Viral Hepat. 11:479-487.
22. Brochot E, Duverlie G, Castelain S, Morel V, Wychowski C, Dubuisson J, Francois C. 2007. Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity. Antivir. Ther. 12:805- 813.
23. Pfeiffer JK, Kirkegaard K. 2005. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J. Virol. 79:2346 -2355.
24. Feigelstock DA, Mihalik KB, Feinstone SM. 2011. Selection of hepatitis C virus resistant to ribavirin. Virol. J. 8:402. doi:10.1186/1743-422X-8 -402.
25. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, Kitamura T, Miyake S. 2005. Mutagenic effects of ribavirin and response to interferon/ ribavirin combination therapy in chronic hepatitis C. J. Hepatol. 43:623- 629.
26. Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL, Lai MM. 2003. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38:869-878.
27. Hofmann WP, Polta A, Herrmann E, Mihm U, Kronenberger B, Sonntag T, Lohmann V, Schonberger B, Zeuzem S, Sarrazin C. 2007. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 132:921-930.
28. Cuevas JM, Gonzalez-Candelas F, Moya A, Sanjuan R. 2009. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol. 83:5760 -5764.
29. Hebner C, Martin R, Miller MD, Mo HM, Svarovskaia ES. 2011. The effects of combining two direct acting antivirals, ribavirin, and pegylated interferon on the detection of drug resistance mutations early in treatment of HCV. Hepatology 54:997a. doi:10.1128/JCM.00838-12.
30. Lutchman G, Danehower S, Song BC, Liang TJ, Hoofnagle JH, Thomson M, Ghany MG. 2007. Mutation rate of the hepatitis C virus NS5B inpatients undergoing treatment with ribavirin monotherapy. Gastroenterology 132:1757-1766.
31. Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM. 2007. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol. 81:7732-7741.
32. Ward CL, Dev A, Rigby S, Symonds WT, Patel K, Zekry A, Pawlotsky JM, McHutchison JG. 2008. Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. J. Viral Hepat. 15:571-577.
33. Zagordi O, Klein R, Daumer M, Beerenwinkel N. 2010. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Res. 38:7400 -7409.
34. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. U. S. A. 87:9524 -9528.
35. Ning Z, Cox AJ, Mullikin JC. 2001. SSAHA: a fast search method for large DNA databases. Genome Res. 11:1725-1729.
36. Oliver GR. 2012. Considerations for clinical read alignment and mutational profiling using next-generation sequencing. F1000 Res. 1:2. doi:10 .3410/f1000research.1-2.v2.
37. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078 -2079.
38. Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNAdependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U. S. A. 100:7289- 7294.
39. Gilles A, Meglecz E, Pech N, Ferreira S, Malausa T, Martin JF. 2011. Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC Genomics 12:245. doi:10.1186/1471-2164-12-245.
40. Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, Leitner T, Lundeberg J, Andersson B, Albert J. 2010. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 5:e11345. doi:10.1371/journal.pone.0011345.
41. Kagan RM, Johnson EP, Siaw M, Biwas P, Chapman DS, Su Z, Platt JL, Pesano RL. 2012. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment- experienced patients. PLoS One 7:e46334. doi:10.1371/journal .pone.0046334.
42. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. 2007. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 17:1195-1201.
43. Niu B, Fu L, Sun S, Li W. 2010. Artificial and natural duplicates in pyrosequencing reads of metagenomic data. BMC Bioinformatics 11:187. doi:10.1186/1471-2105-11-187.
44. Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, Beerenwinkel N. 2012. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat. Commun. 3:811. doi:10.1038 /ncomms1814.
45. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, Bertoni A, Swerdlow HP, Gu Y. 2012. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 13:341. doi:10.1186/1471 -2164-13-341.
46. Noguchi H, Park J, Takagi T. 2006. MetaGene: prokaryotic gene finding from environmental genome shotgun sequences. Nucleic Acids Res. 34: 5623-5630.
47. Keith CS, Hoang DO, Barrett BM, Feigelman B, Nelson MC, Thai H, Baysdorfer C. 1993. Partial sequence analysis of 130 randomly selected maize cDNA clones. Plant Physiol. 101:329 -332.
48. Hoff KJ. 2009. The effect of sequencing errors on metagenomic gene prediction. BMC Genomics 10:520. doi:10.1186/1471-2164-10-520.
49. Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U. S. A. 98:6895- 6900.
50. Lanford RE, Chavez D, Guerra B, Lau JY, Hong Z, Brasky KM, Beames B. 2001. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75:8074-8081.
51. Chung DH, Sun Y, Parker WB, Arterburn JB, Bartolucci A, Jonsson CB. 2007. Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus. J. Virol. 81:11722-11729.
52. Sierra M, Airaksinen A, Gonzalez-Lopez C, Agudo R, Arias A, Domingo E. 2007. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol. 81:2012-2024.
53. Dixit NM, Perelson AS. 2006. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell. Mol. Life Sci. 63:832- 842.
54. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. 2004. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432:922-924.
55. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, Pallen MJ. 2012. Performance comparison of benchtop highthroughput sequencing platforms. Nat. Biotechnol. 30:434-439.
56. Mihm U, Welker MW, Teuber G, Wedemeyer H, Berg T, Sarrazin C, Böhm S, Alshuth U, Herrmann E, Zeuzem S. Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. J. Viral Hepat., in press.